Loading stock data…
$241.89-1.39 (-0.57%)
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.
Quest Diagnostics Incorporated in the Healthcare sector is trading at $241.89 with a market capitalization of $25.9B. Wall Street consensus targets $254.73 (15 analysts), implying a +5.3% move over the next 12 months. The stock is currently near its 52-week high of $248.84, remaining 15.8% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.04B↑ | $2.90B↑ | $2.81B↓ | $2.82B↑ | $2.76B |
| Gross Profit | $1.03B↑ | $942.00M↑ | $910.00M↓ | $949.00M↑ | $943.00M |
| Operating Income | $459.00M↑ | $404.00M↑ | $386.00M | $386.00M↓ | $438.00M |
| Net Income | $320.00M↑ | $252.00M↑ | $245.00M | $245.00M↓ | $282.00M |
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, a...
Academic risk and quality models computed from DGX's own filings and price history, not from analyst opinion.
Strong on 8 of 9 fundamental-health tests covering profitability, leverage and operating efficiency.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
GARCH(1,1) 30-day annualised forecast, level with the current 23.7% reading.
Fama-French 5-factor market beta. The five factors explain 13% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-22.